Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
8.51
-0.10 (-1.16%)
At close: Jun 20, 2025, 4:00 PM
9.65
+1.14 (13.40%)
Pre-market: Jun 23, 2025, 5:24 AM EDT
Nektar Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 87.25 | 98.43 | 90.12 | 92.06 | 101.91 | 152.92 | Upgrade
|
| Revenue Growth (YoY) | -3.24% | 9.21% | -2.10% | -9.67% | -33.36% | 33.41% | Upgrade
|
| Cost of Revenue | 22.15 | 30.69 | 33.77 | 21.64 | 24.9 | 19.48 | Upgrade
|
| Gross Profit | 65.1 | 67.74 | 56.35 | 70.42 | 77.01 | 133.44 | Upgrade
|
| Selling, General & Admin | 80.95 | 76.75 | 77.42 | 92.33 | 122.84 | 104.68 | Upgrade
|
| Research & Development | 123.98 | 120.91 | 114.16 | 218.32 | 400.27 | 408.68 | Upgrade
|
| Operating Expenses | 204.93 | 197.66 | 191.58 | 310.66 | 523.11 | 513.36 | Upgrade
|
| Operating Income | -139.83 | -129.92 | -135.23 | -240.24 | -446.1 | -379.92 | Upgrade
|
| Interest Expense | -27.56 | -28.11 | -25.33 | -28.91 | -47.31 | -37.12 | Upgrade
|
| Interest & Investment Income | 13.15 | 14.5 | 19.01 | 6.78 | 2.73 | 18.28 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.03 | -0.39 | -1.15 | 33.31 | -8.19 | - | Upgrade
|
| EBT Excluding Unusual Items | -158.72 | -143.92 | -142.7 | -229.05 | -498.87 | -398.76 | Upgrade
|
| Merger & Restructuring Charges | -14.86 | -15.67 | -51.96 | -135.93 | - | - | Upgrade
|
| Impairment of Goodwill | - | - | -76.5 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 40.39 | 40.39 | -5.1 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | -24.41 | -45.19 | Upgrade
|
| Pretax Income | -133.19 | -119.2 | -276.26 | -364.98 | -523.28 | -443.95 | Upgrade
|
| Income Tax Expense | -0.15 | -0.24 | -0.2 | 3.22 | 0.56 | 0.49 | Upgrade
|
| Net Income | -133.04 | -118.96 | -276.06 | -368.2 | -523.84 | -444.44 | Upgrade
|
| Net Income to Common | -133.04 | -118.96 | -276.06 | -368.2 | -523.84 | -444.44 | Upgrade
|
| Shares Outstanding (Basic) | 14 | 14 | 13 | 12 | 12 | 12 | Upgrade
|
| Shares Outstanding (Diluted) | 14 | 14 | 13 | 12 | 12 | 12 | Upgrade
|
| Shares Change (YoY) | 9.53% | 8.24% | 1.53% | 2.10% | 2.64% | 2.05% | Upgrade
|
| EPS (Basic) | -9.52 | -8.68 | -21.79 | -29.51 | -42.87 | -37.33 | Upgrade
|
| EPS (Diluted) | -9.52 | -8.68 | -21.79 | -29.55 | -42.90 | -37.33 | Upgrade
|
| Free Cash Flow | -178.19 | -177.18 | -193.47 | -309.68 | -427.65 | -320.55 | Upgrade
|
| Free Cash Flow Per Share | -12.75 | -12.92 | -15.27 | -24.82 | -35.00 | -26.92 | Upgrade
|
| Gross Margin | 74.61% | 68.82% | 62.53% | 76.50% | 75.57% | 87.26% | Upgrade
|
| Operating Margin | -160.27% | -131.99% | -150.05% | -260.97% | -437.76% | -248.45% | Upgrade
|
| Profit Margin | -152.49% | -120.86% | -306.31% | -399.98% | -514.03% | -290.64% | Upgrade
|
| Free Cash Flow Margin | -204.23% | -180.01% | -214.68% | -336.41% | -419.65% | -209.62% | Upgrade
|
| EBITDA | -136.62 | -125.53 | -127.41 | -227.21 | -431.96 | -365.74 | Upgrade
|
| EBITDA Margin | -156.59% | -127.53% | -141.38% | -246.81% | - | -239.18% | Upgrade
|
| D&A For EBITDA | 3.21 | 4.39 | 7.82 | 13.03 | 14.15 | 14.18 | Upgrade
|
| EBIT | -139.83 | -129.92 | -135.23 | -240.24 | -446.1 | -379.92 | Upgrade
|
| EBIT Margin | -160.27% | -131.99% | -150.05% | -260.97% | - | -248.45% | Upgrade
|
| Revenue as Reported | 87.25 | 98.43 | 90.12 | 92.06 | 101.91 | 152.92 | Upgrade
|
Updated Mar 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.